Search Results
Your search for ,LAB matches 1039 pages
Showing 101 - 150Benjamin Besse, MD, PhD, Chooses a Career in Medicine Over Music
In this installment of The ASCO Post’s Living a Full Life series, guest editor Jame Abraham, MD, FACP, spoke with Benjamin Besse, MD, PhD, Professor of Medical Oncology at Paris-Saclay University, Orsay, France, and lung cancer specialist at Gustave Roussy Cancer Campus, Villejuif. Currently, Dr....
Examining Disparities in Endometrial Cancer Outcomes Among Black Patients
Black patients with stage IA low-grade endometrioid endometrial carcinoma may be less likely to undergo a hysterectomy and survive their cancer than White patients with the same type of cancer, according to a recent study published by Taylor et al in Gynecologic Oncology. Background “We’ve known...
How Is Administrative Payment Burden Associated With Cost-Related Delays in Cancer Care?
Research shows that the United States’ health-care delivery and financing system is so complex that streamlining administrative costs alone could reduce total health-care spending by 15%. In addition, health insurance payment and medical billing processes are time-consuming and expensive for both...
Therapeutic Implications of DNA Repair Discoveries in Patients With Homologous Recombination Deficiencies
Long-molecule scars may help identify patients with BRCA1- and BRCA2-deficient cancer types, according to a recent study published by Setton et al in Nature. Background Once DNA is damaged by toxins, radiation, or normal cell division, human cells must continually fix DNA breaks to survive. When...
Niraparib Maintenance in Newly Diagnosed Advanced Ovarian Cancer
In a Chinese phase III study reported in JAMA Oncology, Li et al found that niraparib maintenance therapy given with an individualized starting dose improved progression-free survival vs placebo in newly diagnosed patients with advanced ovarian cancer. Study Details In the double-blind multicenter...
Alfredo Quiñones-Hinojosa, MD: From Migrant Farm Worker to Neurosurgeon in Search of a Cure for Brain Cancer
In this installment of The ASCO Post’s Living a Full Life series, guest editor Jame Abraham, MD, FACP, spoke with neurosurgeon Alfredo Quiñones-Hinojosa, MD, FAANS, FACS, the James C. and Sarah K. Kennedy Dean of Research, Monica Flynn Jacoby Chair of Neurologic Surgery, and William J. and Charles...
Overweight and Obese BMI May Be Linked to Adverse Treatment Outcomes in AYA Patients With ALL
An elevated body mass index (BMI) could potentially be associated with inferior treatment outcomes in adolescent and young adult (AYA) patients with acute lymphoblastic leukemia (ALL), according to a new study published by Shimony et al in Blood Advances. The findings may demonstrate the impact of...
Fecal Microbiota Transplants Show Potential in Improving Melanoma Treatment
Researchers have found that fecal microbiota transplants from healthy donors may be safe and show potential in improving response rates to immunotherapy in patients with advanced melanoma, according to a phase I study published by Routy et al in Nature Medicine. Background While immunotherapy...
Goals of Care in Primary Myelofibrosis
This is Part 3 of Updates in Myeloproliferative Neoplasms, a three-part video roundtable series. In this video, Dr. Naveen Pemmaraju and Dr. Gabriela Hobbs discuss goals of care in primary myelofibrosis. The patient is a 27-year-old woman who presents to the clinic after 6 months of...
DUO-O: Benefit Shown for Durvalumab Plus Olaparib in Advanced Ovarian Cancer
In newly diagnosed advanced ovarian cancer lacking a BRCA mutation, the addition of durvalumab and olaparib to standard therapy significantly improved progression-free survival, in a planned interim analysis of the international phase III DUO-O trial presented at the 2023 ASCO Annual Meeting1 and...
Toripalimab Plus Chemotherapy Improves Event-Free Survival in Resectable Stage III NSCLC
Findings from a phase III, randomized trial highlight the benefit derived from perioperative immunotherapy in patients with early-stage resectable non–small cell lung cancer (NSCLC), according to data presented during the ASCO Plenary Series: April 2023 Session.1 Interim analysis of the Neotorch...
Finding Early Female Role Models Helped Shape a Notable Career in Oncology
Elizabeth M. Jaffee, MD, Deputy Director of The Sidney Kimmel Comprehensive Cancer Center, Baltimore, was born in Brooklyn, New York, in a place and time she found exhilarating during her early years. “We didn’t have a lot of money—actually, we were poor. But I had a lot of freedom walking around...
ASCO Congratulates 2023 Special Awards Recipients
ASCO and Conquer Cancer, the ASCO Foundation, will recognize researchers, patient advocates, philanthropists, teachers, and global oncology leaders who have reshaped cancer care with the Society’s highest honors at the 2023 ASCO Annual Meeting in Chicago. Hear from select award recipients at the...
An Oncology Leader Whose Immigrant Parents Taught Him by Example About Life and Service to Humanity
According to Sunil R. Hingorani, MD, PhD, his parents figured heavily on who he became as a person and on his career choices, which ultimately led to his current position as Director of the Pancreatic Cancer Center of Excellence at the University of Nebraska College of Medicine, Omaha. “My father...
The Second-Generation Son of Greek Immigrants, the First to Go to College, Becomes a Leader in Sarcoma Research and Treatment
George D. Demetri, MD, FASCO, Director of the Sarcoma Center at Dana-Farber Cancer Institute, and Professor of Medicine and Co-Director of the Ludwig Center at Harvard, was born in Hyde Park, a town along the Hudson River in New York. When Dr. Demetri was growing up there, it was known for three...
Mourned and Missed
The respected members of the oncology community listed here are among some of those who passed away in 2022–2023. The ASCO Post remembers them, their lives, and their contributions to cancer research and treatment. Robert J. Gillies, PhD Moffitt Cancer Center and the global research community lost ...
A Love of Immunology Leads to a Notable Career in Dermatology, With a Focus on Melanoma Research and Treatment
Caroline Robert, MD, PhD, Head of the Dermatology Unit at Gustave Roussy and Co-Director of the Melanoma Research Unit at INSERM 981 Paris-Sud University, was born and reared in Paris. “I didn’t have a vocation for medicine when I was a kid; I wanted to be an archeologist. I’m not from a medical...
From a Small Town in North Carolina, a Young Girl Finds Her Calling in Battling Inequity in Cancer Care
Manali Patel, MD, MPH, Associate Professor of Medicine (Oncology) at Stanford University, grew up in Shelby, a small town in the textile and farming community of Western North Carolina, among mill workers and other blue-collar laborers. The daughter of Indian immigrants, Dr. Patel’s early life was...
ASCO Congratulates 2023 Special Awards Recipients
ASCO and Conquer Cancer, the ASCO Foundation, will recognize researchers, patient advocates, philanthropists, teachers, and global oncology leaders who have reshaped cancer care around the world with the Society’s highest honors at the 2023 ASCO Annual Meeting in Chicago. Hear from select award...
Surviving, but Not Always Thriving, After Cancer
The improvement in cancer survival rates since President Richard M. Nixon signed the National Cancer Act of 1971 into law is staggering. The legislation further committed the United States to greater investments in cancer-focused research to drive down the rates of cancer diagnoses, boost patient...
WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues
The ASCO Post is pleased to present Hematology Expert Review, an ongoing feature that quizzes readers on issues in hematology. In this installment, Drs. Syed Ali Abutalib and L. Jeffrey Medeiros explore the World Health Organization (WHO) classification of hematopoietic and lymphoid tissue...
Israeli Surgical Oncology Leader Dov Zippel, MD, Considers the Evolving Landscape of Cancer Care in a Small Nation
In this installment of The ASCO Post’s Global Oncology series, Guest Editor Chandrakanth Are, MBBS, MBA, FRCS, FACS, spoke with Dov Zippel, MD, a surgical oncologist at Sheba Medical Center in Tel Hashomer, Israel, where he is Head of the Meirav Breast Center. Dr. Zippel is the current President of ...
Checkpoint Inhibitors Poised to Change Standard of Care in Advanced Endometrial Cancer
The addition of a checkpoint inhibitor to standard chemotherapy as first-line treatment of advanced endometrial cancer reduced the risk of disease progression or death by 70% in patients with mismatch repair–deficient (dMMR) tumors in two recent phase III studies. The results of the two...
Study Finds Cancer-Related Emergency Department Visits Increased by 67%, Mainly Because of Uncontrolled Pain
Emergency department (ED) visits by patients with cancer increased by 67.1% between the start of 2012 and the end of 2019, compared with an increase of just 7.5% in cancer incidence, according to a recent study in JAMA Network Open.1 Factors identified as possible explanations for the...
Checkpoint Inhibitors Poised to Change Standard of Care in Advanced Endometrial Cancer
The addition of a checkpoint inhibitor to standard chemotherapy as first-line treatment of advanced endometrial cancer reduced the risk of disease progression or death by 70% in patients with mismatch repair–deficient (dMMR) tumors in two recent phase III studies. The results of the two...
Study Finds Precursor Pancreatic Lesions Occur Frequently in Healthy Human Pancreases
Pancreatic cancer is a rare disease, accounting for about 3% of all cancers in the United States. It is the deadliest of all solid malignancies, accounting for about 7% of all cancer deaths each year, and carries a 5-year survival rate of just 11.5%. According to the American Cancer Society, in...
Surgeon and Cancer Researcher Kelly M. McMasters, MD, PhD, Celebrates the ‘Miracle of Translational Science’
In this installment of our Global Oncology series, Guest Editor Chandrakanth Are, MBBS, MBA, FRCS, FACS, spoke with Kelly M. McMasters, MD, PhD, who, for the past 27 years, has directed a basic and translational science lab studying adenovirus-mediated cancer gene therapy and melanoma biomarkers....
Researchers Uncover How Advanced Melanoma May Resist Treatment at the End of Life
Researchers have revealed the potential mechanisms contributing to treatment resistance in patients with melanoma at the end of life, according to a new study published by Spain et al in Cancer Discovery. “These results present the most detailed picture yet of what melanoma looks like at the final...
Obesity May Contribute to Breast Cancer Risk in High-Risk Patients With BRCA Mutations
Obesity may spur DNA damage in the breast tissue of patients who carry BRCA1 or BRCA2 mutations, possibly contributing to breast cancer development in patients who are already at a higher risk of the disease, according to a new study published by Bhardwaj et al in Science Translational Medicine....
A Pioneering Oncologist, a Pilot, and a Choral Singer, Among Other Things
“There is and always has been, more to me than medicine. Ever since the university, I have loved flying. Ever since school, I have adored choral singing,” writes John F. Smyth, MD, in his memoir Taming the Beast: Memoirs of a Pioneering Cancer Physician. Dr. Smyth is Emeritus Professor of Medical...
Whole-Genome Sequencing May Illuminate the Genetic Evolution of Classical Hodgkin Lymphoma
Researchers have discovered that whole-genome sequencing—rather than the current standard of exome sequencing—may allow physicians to better identify genetic changes that drive cancer development and growth, and create the most effective, personalized treatment plans for patients with classical...
MD Anderson’s Guillermina Lozano, PhD, Receives AAMC Award for Distinguished Research in the Biomedical Sciences
In recognition of her work in uncovering the mechanisms of the p53 tumor suppressor, Guillermina “Gigi” Lozano, PhD, Chair of Genetics at The University of Texas MD Anderson Cancer Center, Houston, has received the 2022 Award for Distinguished Research in the Biomedical Sciences by the Association...
Oncologists Look for Strong Health-Care Priorities in the State of the Union Address
In anticipation of President Joseph R. Biden’s State of the Union Address tonight, ASCO is urging the president to keep cancer care and research as top national priorities. Oncologists have seen how clinical research has improved prevention, detection, and treatment for millions of Americans and...
Challenges of Accurately Identifying HER2-Low Breast Cancers
The newly identified category of “HER2-low” breast cancer has raised many new issues in this malignancy now that the DESTINY Breast-041 trial determined that fam-trastuzumab deruxtecan-nxki (T-DXd) may effectively treat this tumor. Among the issues are challenges in accurately identifying just...
Researchers Develop AI Algorithm to Gain New Insights Into Glioblastoma
Researchers have developed an artificial intelligence (AI) algorithm, known as SPHINKS, capable of performing advanced computational analyses to identify potential therapeutic targets for patients with glioblastoma multiforme. The platform may also have applicability in other cancers, according to...
Andrea Schietinger, PhD, to Present 2023 AACR–Irving Weinstein Foundation Distinguished Lecture
The American Association for Cancer Research (AACR) will award the 19th AACR–Irving Weinstein Foundation Distinguished Lectureship to Andrea Schietinger, PhD, during the 2023 AACR Annual Meeting, held April 14–19, in Orlando, Florida. Dr. Schietinger, an associate member of the Immunology Program...
Phase III NORA Trial: Niraparib Maintenance Shows Overall Survival Trend in Platinum-Sensitive Recurrent Ovarian Cancer
Maintenance therapy with a poly (ADP-ribose) polymerase (PARP) inhibitor may do more than just delay disease progression for patients with platinum-sensitive, relapsed ovarian cancer; it might also improve overall survival, according to data presented during the December 2022 European Society for...
A Serendipitous Opportunity Steers a Theater Major Into Oncology
Lymphoma expert Jeremy S. Abramson, MD, was born in Westchester County, New York, but soon after, his family relocated to Bergen County, New Jersey, where he spent his formative years. “I attended Tenafly High School and had dual passions: one was the natural sciences and the other on the...
Maureen Murphy, PhD, Named Deputy Director of the Wistar Institute’s Ellen and Ronald Caplan Cancer Center
The Ellen and Ronald Caplan Cancer Center at The Wistar Institute, Philadelphia, has announced the appointment of the Ira Brind Endowed Professor, Maureen Murphy, PhD, as Deputy Director. Dr. Murphy will guide the growth of the Cancer Center through expanding research initiatives and collaboration, ...
Expert Point of View: Debu Tripathy, MD
Debu Tripathy, MD, Professor of Medicine and Chair of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, said that the study points the way to further exploration of the benefit of adding immunotherapy to treatment after patients develop resistance to CDK4/6 inhibitors for ...
Neoadjuvant T-DXd Demonstrates Activity in Phase II Study of Patients With HER2-Low Breast Cancer
A pilot study provides a signal that the novel HER2 antibody-drug conjugate fam-trastuzumab deruxtecan-nxki (T-DXd), is active in the neoadjuvant setting in patients with HER2-low breast cancer. Overall response rates were 75% with T-DXd alone and 63% when T-DXd was combined with endocrine therapy...
Immune System B Cells May Help to Predict Treatment Response Among Patients With HER2-Positive Breast Cancer
Researchers have found that measuring the activation of immune system B cells may be more effective than measuring the activation of either T cells or tumor-infiltrating lymphocytes (TILs) in predicting whether patients with HER2-positive breast cancer will respond to treatment. These findings were ...
Triple Immunotherapy Combination Studied Preclinically for Pancreatic Cancer
Researchers at The University of Texas MD Anderson Cancer Center have discovered a novel immunotherapy combination, targeting checkpoints in both T cells and myeloid suppressor cells, that successfully reprogrammed the tumor immune microenvironment and significantly improved antitumor responses in...
A Lifelong Love of Science Leads to a Leadership Role in Oncology for Laurie Glimcher, MD
For this installment of The ASCO Post’s Living a Full Life series, Guest Editor Jame Abraham, MD, FACP, spoke with Laurie Glimcher, MD, President and Chief Executive Officer (CEO) of Dana-Farber Cancer Institute (DFCI). She is also Director of the Dana-Farber/Harvard Cancer Center, Principal...
From the Clinic to the Lab: Overcoming Resistance to Immune Checkpoint Therapy
As a result of breakthroughs in immune checkpoint inhibitors over the past decade, immunotherapy has joined surgery, radiation therapy, and chemotherapy as one of the pillars of cancer treatment. However, nearly half of patients still do not benefit from immune checkpoint blockade. During the 2022...
Research Exposes Inequities in Health-Care Access and Delivery for Blood Disorders
Several studies presented during the 2022 American Society of Hematology (ASH) Annual Meeting and Exposition uncovered significant disparities in medical care and health outcomes among patients of different racial backgrounds, nationalities, and socioeconomic status across a range of blood...
Phase III NORA Study: Niraparib Maintenance Shows Favorable Overall Survival Trend in Platinum-Sensitive Recurrent Ovarian Cancer
Poly (ADP-ribose) polymerase (PARP) inhibitor maintenance therapy may do more than just delay disease progression for patients with platinum-sensitive, relapsed ovarian cancer; it might also improve overall survival, according to data presented by Mansoor Raza Mirza, MD, during the December Virtual ...
Fox Chase Receives $6 Million Grant as Founding Member of New NCI Prevention Initiative
Fox Chase Cancer Center was recently awarded a grant for $6 million over the course of 5 years to develop a new Cancer Prevention-Interception Targeted Agent Discovery Program (CAP-IT). The new National Cancer Institute (NCI) program was created to establish a pipeline for the discovery of new...
Pilot Study Investigates Axicabtagene Ciloleucel in Primary and Secondary CNS Lymphoma
The chimeric antigen receptor (CAR) T-cell therapy axicabtagene ciloleucel was deemed safe and showed encouraging signs of efficacy in a small pilot trial involving patients with lymphoma of the brain and/or spinal cord, according to findings presented by Caron A. Jacobson, MD, MMSc, and colleagues ...
Clinical Trial Lab-Based Eligibility Criteria Disproportionately Excluded Non-White Patients With DLBCL From Study Participation
A previous analysis by Khurana et al on the impact of inclusion/exclusion criteria in clinical trial design for patients with diffuse large B-cell lymphoma (DLBCL) found that up to 24% of patients treated with standard immunochemotherapy were excluded based on five lab-based criteria alone. A new...
